Suggested remit: To appraise the clinical and cost effectiveness of retifanlimab within its marketing authorisation for treating anal canal squamous cell carcinoma after platinum-based chemotherapy.
Status In progress
Process STA 2018
ID number 3815

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
02 June 2021 - 30 June 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 October 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance